Literature DB >> 6611150

The effects of iodine and thiol-blocking reagents on complement component C2 and on the assembly of the classical-pathway C3 convertase.

M A Kerr, C Parkes.   

Abstract

I2 can react with complement component C2 in a two-stage process. In the first stage, a form of C2 with enhanced haemolytic activity is produced. This form of C2 is cleaved to C2a and C2b by C1s at the same rate as native C2. The enhanced C2 haemolytic activity correlates with the ability to form a stable fluid-phase C3 convertase on addition of the C2 to C4b and C1s. It reflects an increased affinity for C4b of C2a formed from I2-treated C2, although the affinity for C4b of I2-treated C2 itself is not markedly increased. The specific activity of C3 convertase formed from I2-treated C2 is the same as that formed from native C2. The second stage of the reaction with I2, which is favoured at high pH or in the presence of excess I2, inactivates C2 on production of a species that cannot be cleaved by C1s. The presence of a single free thiol group in C2, which is the site of modification by I2, was confirmed by titration with p-chloromercuribenzoate, iodoacetamide and 5,5'-dithiobis-(2-nitrobenzoic acid). A single thiol group is also present in Factor B, and the cysteine residue, like that in C2, requires denaturation of the protein before reaction with iodoacetamide and 5,5'-dithiobis-(2-nitrobenzoic acid) but not p-chloro- mercuribenzoate .

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6611150      PMCID: PMC1153493          DOI: 10.1042/bj2190391

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  15 in total

1.  The unactivated form of the first component of human complement, C1.

Authors:  I Gigli; R R Porter; R B Sim
Journal:  Biochem J       Date:  1976-09-01       Impact factor: 3.857

2.  The purification and properties of the second component of human complement.

Authors:  M A Kerr; R R Porter
Journal:  Biochem J       Date:  1978-04-01       Impact factor: 3.857

3.  A study of the sulfhydryl groups of the catalytic subunit of Escherichia coli aspartate transcarbamylase. The use of enzyme--5-thio-2-nitrobenzoate mixed disulfides as intermediates in modifying enzyme sulfhydryl groups.

Authors:  T C Vanaman; G R Stark
Journal:  J Biol Chem       Date:  1970-07-25       Impact factor: 5.157

4.  The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis.

Authors:  N R Cooper; M J Polley; H J Müller-Eberhard
Journal:  Immunochemistry       Date:  1970-04

Review 5.  Molecular biology and chemistry of the alternative pathway of complement.

Authors:  H J Müller-Eberhard; R D Schreiber
Journal:  Adv Immunol       Date:  1980       Impact factor: 3.543

6.  Partial sequence of human complement component factor B: novel type of serine protease.

Authors:  D L Christie; J Gagnon; R R Porter
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

7.  Cleavage of C2 by C1s into the antigenically distinct fragments C2a and C2b: demonstration of binding of C2b to C4b.

Authors:  S Nagasawa; R M Stroud
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

8.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

9.  The alternative pathway C3/C5 convertase: chemical basis of factor B activation.

Authors:  P H Lesavre; T E Hugli; A F Esser; H J Müller-Eberhard
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

10.  Enharncement of the hemolytic activity of the second component of human complement by oxidation.

Authors:  M J Polley; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1967-12-01       Impact factor: 14.307

View more
  2 in total

1.  The extracellular adherence protein from Staphylococcus aureus inhibits the classical and lectin pathways of complement by blocking formation of the C3 proconvertase.

Authors:  Jordan L Woehl; Daphne A C Stapels; Brandon L Garcia; Kasra X Ramyar; Andrew Keightley; Maartje Ruyken; Maria Syriga; Georgia Sfyroera; Alexander B Weber; Michal Zolkiewski; Daniel Ricklin; John D Lambris; Suzan H M Rooijakkers; Brian V Geisbrecht
Journal:  J Immunol       Date:  2014-11-07       Impact factor: 5.422

2.  Cleavage of the second component of complement by plasma proteases: implications in hereditary C1-inhibitor deficiency.

Authors:  M A Smith; M A Kerr
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.